Cachexia is a syndrome characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite, and is thought to be directly responsible for 20% of cancer deaths in the United States. It is far too common, being present in at least 50% of people with advanced cancer. In addition to weight loss and muscle wasting, symptoms usually include a lower quality of life. Cancer cachexia is also referred to as cancer anorexia cachexia syndrome.

Cachexia is diagnosed by looking at a combination of body mass index (a calculation based on height and weight), lean muscle mass, and blood tests. Since cachexia is thought to often be present even before weight loss occurs, a high index of suspicion is important in recognizing the condition as soon as possible. A number of treatment approaches have been evaluated ranging from diet to dietary supplements, to medications, but can be challenging as cachexia is more than just a lack of calories in the body. Newer research suggests that exercise, though counterintuitive, may help. Compounds such as one type of omega-3-fatty acid (fish oil) have shown promise in reducing the complications of the condition, and newer therapies such as androgen receptor modulators and more are being evaluated in clinical trials.

Cachexia is sometimes referred to as a paraneoplastic syndrome, which simply means symptoms that are caused by substances made by cancer or by the body's reaction to cancer.

Cachexia not only worsens survival for people with cancer, but it interferes with quality of life. People with cachexia are less able to tolerate treatments, such as chemotherapy, and often have more side effects. For those who have surgery, postoperative complications are more common. Cachexia also worsens cancer fatigue, one of the most annoying symptoms of cancer.

Recent research suggests that cachexia often begins even before any weight loss occurs, so early on there may not be any symptoms. When symptoms occur, they include:

Weight loss with cachexia is involuntary, meaning that it occurs without trying. Yet it goes further than unexplained weight loss. Weight loss may occur even though you are getting an adequate amount of calories in your diet, and if calorie intake outweighs output of energy. Unintentional weight loss is defined as the loss of 5% of body weight over a 6 month to 12 month period, but even smaller amounts of weight loss could be of concern.

Muscle wasting is a hallmark of cachexia and occurs along with a loss of fat. It can also be fairly insidious. In people who are overweight at the time of their diagnosis, significant loss of muscle mass can occur without an obvious outward appearance of weight loss.

Loss of appetite is another symptom of cachexia, and again, this symptom is somewhat different than ordinary "loss of appetite" symptoms. With cachexia, it is not simply a decreased desire for food, but more of a loss of a desire to eat.

Muscle wasting can diminish your ability to walk and participate in activities that would ordinarily be enjoyable.

Cachexia may be caused by "tumor factors," substances manufactured and secreted by a tumor, or by the "host response." Host response simply means the body's response to a tumor. The response of the immune system to cancer and other causes of cachexia are being studied to try and understand the underlying factors behind cachexia.

Cachexia is dominated by catabolic metabolism. If you think of normal metabolism being the building of tissue and muscle (anabolic metabolism), the opposite is true with cachexia, which is the breakdown of normal bodily processes.

Cachexia is seen frequently with cancer but is also seen with diseases such as AIDS/HIV, heart failure, emphysema, and kidney failure. With regard to cancer, it is seen most frequently with lung cancer, pancreatic cancer, and stomach cancer, but may be seen with any type of advanced cancer.

Even though the symptoms and signs of cachexia are usually noticed late in the course of cancer, we're learning that the process leading to muscle wasting begins very early on after a diagnosis of cancer. As such, cachexia is often present before any weight loss occurs.

There are several ways that cachexia can be evaluated. Some of these measures include:

There are a number of screening tools that look at combination of the above in order to identify cachexia, such as the Malnutrition Universal Screening Tool (MUST), though there is not yet a single screening tool that is effective in detecting cachexia in every case. Dividing cachexia into stages or grades can give healthcare providers a better of the natural history of cachexia, but of greatest concern is that cachexia is diagnosed as early as possible.

Despite the number of tools available, following a person over time and checking serial body weights can give a better idea of changes.

Researchers have developed a cachexia staging score for people with advanced cancer. A different number of points are assigned to each component and added together to separate cachexia into three stages. These components include:

Based on scoring, precachexia and cachexia can then be broken down into four stages:

A study published in 2015 in the Journal of Clinical Oncology divided cancer cachexia into 5 grades. Researchers found that for each increase in grade, survival decreased significantly. Grades were as follows:

The first step in treatment is to treat any physical symptoms or conditions that could lead to a decreased appetite or ability to eat. These include:

In many cases, simple changes in diet can reduce symptoms, such as eating with plastic utensils if you have "metal mouth" or choosing foods to manage gastroparesis.

An evaluation should also be done to rule out hyperthyroidism (thyroid conditions are common with cancer treatment), and conditions such as adrenal insufficiency or hypogonadism should also be considered.

Treatment approaches to date have been fairly disappointing, and even with adequate calorie intake, it is difficult to reverse the process of cachexia.

The aim of treatment is to stimulate "anabolic processes" (that is, muscle building) while inhibiting "catabolic processes" (the actions that result in the breakdown of muscle).

At the current time, most researchers believe a combination of treatments (multimodality therapy) is essential. Treatment options include:

Contrary to what may seem obvious, replacing and supplementing calories in the diet has not made a big difference in the syndrome of cachexia. That said, it's very important to make sure that people coping with cancer (and similar conditions that cause cachexia) have a healthy diet. One important point to keep in mind is that if someone has not been eating much for a period of time, intake should be increased gradually. If calories are pushed too rapidly, a side effect called "overfeeding syndrome" may occur. When eating is not possible (or is limited) orally, a feeding tube may be recommended.

Many healthcare providers recommend eating frequent small meals with an emphasis on calorie-dense foods.

Nutrition counseling may be helpful in addressing any symptoms that lead to decreased intake and giving you ideas on foods to try that you may not have thought about.

Nutritional supplements such as ensure are often recommended, but should not be used as a substitute for meals. It's usually recommended that when used, these products should be consumed between meals.

It's ideal if nutrients can be obtained through food, but we know that's not always the case. Fish oil has been evaluated for its ability to treat cachexia with some studies (but not all) suggesting it may be helpful. In one study, adding a powder supplement of eicosapentaenoic acid (EPA), one of the main three omega-3 fatty acids that people get in their diets by eating fish, improved the levels of inflammatory markers that go along with cachexia. Supplements of EPA were also linked with shorter hospital stays and fewer infections and complications.

Centers focused on recognizing and treating cachexia also often recommend amino acid supplements, particularly glutamine, L-Carnitine and L arginine, and these amino acids are being evaluated in combination with other therapies to assess their potential benefit.

It may seem counterintuitive, but increasing activity (if possible) may help. An obvious benefit of exercise is increased appetite, but endurance training may go beyond eating habits to help slow the decline in muscle mass seen with cachexia. It's thought that exercise may reduce inflammation and also affect metabolism in muscles themselves.

Appetite stimulants have been used for treating cachexia, though their effects are unclear. These include:

Anti-inflammatory medications such as Celebrex (celecoxib) have shown some promise, particularly if evidence of inflammation is present (for example, if C reactive protein is elevated). There is some evidence with head and neck cancer that these medications may improve prognosis.

Thus far the evidence for the use of cannabis for cancer-related cachexia-anorexia is equivocal. Hopefully, with changes in regulations leading to a greater ability to study substances such as THC and CBD in clinical trials, the question of their efficacy will be answered.

A wide range of medications have been investigated to some degree for their potential role in addressing cachexia. Both selective androgen receptor modulators and medications that target the ghrelin receptor (ghrelin is the hunger hormone) are being studied. Drugs that target inflammatory compounds such as cytokines (cytokines contribute to muscle breakdown) are intriguing. The body produces cytokines to help kill cancer cells, but cytokines also tend to shift the body towards a state of catabolism (breakdown). Finally, as with many conditions, efforts to target gut bacteria deserves further study.

As with so many issues regarding cancer, it's important to be your own advocate in your care. Studies tell us that cachexia in cancer is an unmet need, and that screening for and treatment approaches for cachexia vary widely around the country. If you are living with cancer, and especially if you have experienced a loss of appetite or any weight loss, talk to your healthcare provider about cachexia. While the intake of calories isn't the whole answer in preventing or treating cachexia, it does play a role. If you are struggling with your appetite, talking with an oncology nutritionist may help. If you have symptoms that are limiting your ability to eat, such as shortness of breath, difficulty swallowing, or more, talk to your healthcare provider. Sometimes working with a palliative care team can be invaluable in addressing the annoying symptoms related to cancer and cancer treatments, allowing people to live their best life possible with this disease.

Yes, various steroids and hormone drugs are used as appetite stimulants to treat cachexia in people with cancer. Some of these include prednisone, dexamethasone, Megace (megestrol), medroxyprogesterone, and testosterone. The effects of these stimulants are unclear.

One study of an appetite stimulant called megestrol acetate (MA) found that for people with cachexia syndrome, it is associated with a greater risk of blood clots, fluid retention (which causes foot and hand swelling), and even death.

Symptoms of cachexia can include involuntary weight loss, muscle wasting, and appetite loss (more specifically, a loss of the desire to eat). Involuntary weight loss is defined as losing 5% of body weight over a period of six to 12 months.

Limiting processed foods and red meats can help ward off cancer risk. These recipes focus on antioxidant-rich foods to better protect you and your loved ones. Sign up and get your guide!

Thank you, {{form.email}}, for signing up.

There was an error. Please try again.

Dev R. Measuring cachexia-diagnostic criteria. Annals of Palliative Medicine. 2019. 8(1):24-32. doi:10.21037/apm.2018.08.07

Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. Journal of Clinical Oncology. 2015. 33(1):90-9. doi:10.1200/JCO.2014.56.1894

Lai V, George J, Richey L, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008;30(1):67-74. doi:10.1002/hed.20662

Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310. doi:10.1002/14651858.CD004310.pub3

Advani SM, Advani PG, VonVille HM, Jafri SH. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. BMC Cancer. 2018. 18(1):1174. doi:10.1186/s12885-018-5080-4

Dev R, Wong A, Hui D, Bruera E. The Evolving Approach to Management of Cancer Cachexia. Oncology (Williston Park). 2017. 31(1):23-32.

Dev R. Measuring cachexia-diagnostic criteria. Annals of Palliative Medicine. 2019. 8(1):24-32. doi:10.21037/apm.2018.08.07

Fearon K, Strasser F, Anker SD, et al. Definition and Classification of Cancer Cachexia: an International Consensus. Lancet Oncology. 2011. 12(5):489-95. doi:10.1016/S1470-2045(10)70218-7

Genton L, Mareschal J, Charretier Y, et al. Targeting the Gut Microbiota to Treat Cachexia. Frontiers in Cellular and Infection Microbiology. 2019. 9:305. doi:10.3389/fcimb.2019.00305

Martin L, Kubrak C. How Much Does Reduced Food Intake Contribute to Cancer-Associated Weight Loss. Current Opinion in Supportive and Palliative Care. 2018. 12(4):410-419 doi:10.1097/SPC.0000000000000379

Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. Journal of Clinical Oncology. 2015. 33(1):90-9. doi:10.1200/JCO.2014.56.1894

Schcolnik-Cabrera A, Chavez-Blanco A, Dominquez-Gomez G, Duenas-Gonzalez A. Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. American Journal of Cancer Research. 2017. 7(5): 1107–1135.

Wang J, Wang Y, Tong M, Pan H, Li D. Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis. BioMed Research International. 2019:2864384. doi:10.1155/2019/2864384

Thank you, {{form.email}}, for signing up.

There was an error. Please try again.